LONG-TERM BEVACIZUMAB TREATMENT IN PATIENTS WITH METASTATIC COLORECTAL CANCER WHO ARE RECEIVING FOLFOX4 AND FOLFIRI CHEMOTHERAPY

被引：0
|
作者：
Davidenko, Irina [1 ]
Kazantseva, Margarita [2 ]
Potemin, Sergey [2 ]
Elizbaryan, Karina [2 ]
Mamaeva, Elena [2 ]
Burdik, Oksana [2 ]
机构：
[1] Krasnodar City Oncol Ctr, Krasnodar, Russia
[2] Krasnodar Oncol Ctr, Krasnodar, Russia
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：98 / 98
页数：1
相关论文
共 50 条
  • [41] Biochemical liver function test parameter levels in relation to treatment response in liver metastatic colorectal patients treated with FOLFOX4 with or without bevacizumab
    Denic, Kristina
    Tarabar, Dino
    Obradovic, Slobodan
    Ristic, Marija
    Spasic, Jelena
    Radosavljevic, Davorin
    Ugresic, Nenad
    SRPSKI ARHIV ZA CELOKUPNO LEKARSTVO, 2016, 144 (11-12) : 615 - 620
  • [42] A Randomized Phase II Trial of Vismodegib versus Placebo with FOLFOX or FOLFIRI and Bevacizumab in Patients with Previously Untreated Metastatic Colorectal Cancer
    Berlin, Jordan
    Bendell, Johanna C.
    Hart, Lowell L.
    Firdaus, Irfan
    Gore, Ira
    Hermann, Robert C.
    Mulcahy, Mary F.
    Zalupski, Mark M.
    Mackey, Howard M.
    Yauch, Robert L.
    Graham, Richard A.
    Bray, Gordon L.
    Low, Jennifer A.
    CLINICAL CANCER RESEARCH, 2013, 19 (01) : 258 - 267
  • [43] Axitinib or bevacizumab (bev) plus FOLFOX or FOLFIRI as second-line therapy in patients (pts) with metastatic colorectal cancer (mCRC)
    Bendell, J. C.
    Tournigand, C.
    Bednarczyk, M.
    Swieboda-Sadlej, A.
    Chung, I.
    Barone, C.
    Tarazi, J. C.
    Rosbrook, B.
    Ricart, A. D.
    Sobrero, A. F.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [44] Clubbing and hypertrophic osteoarthropathy in two patients taking long-term bevacizumab for metastatic colorectal cancer
    Pracht M.
    Le Roux C.
    Kerjouan M.
    Boucher E.
    Audrain O.
    Raoul J.-L.
    Journal of Gastrointestinal Cancer, 2011, 42 (3) : 176 - 178
  • [45] The opus study: Predictive value of KRAS status on clinical outcome in patients with metastatic colorectal cancer treated with either FOLFOX4 or FOLFOX4 plus cetuximas
    Schuch, G.
    Bondarenko, I
    Hartmann, J.
    De Braud, F.
    Volovat, C.
    Nippgen, J.
    Stroh, C.
    Celik, I
    Koralewski, P.
    Bokemeyer, C.
    ANNALS OF ONCOLOGY, 2008, 19 : 18 - 18
  • [46] Long-Term Treatment of Metastatic Colorectal Cancer with Panitumumab
    Lopez-Gomez, Miriam
    Merino, Maria
    Casado, Enrique
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2012, 6
  • [47] Modified FOLFOX-6 Plus Bevacizumab Chemotherapy for Metastatic Colorectal Cancer in Patients Receiving Hemodialysis: A Report of Three Cases and Review of the Literature
    Funasaka, Chikako
    Kanemasa, Yusuke
    Shimoyama, Tatsu
    Ohta, Akihito
    Omuro, Yasushi
    CASE REPORTS IN ONCOLOGY, 2019, 12 (02): : 657 - 665
  • [48] FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer
    Bokemeyer, C.
    Koehne, C. -H.
    Ciardiello, F.
    Lenz, H. -J.
    Heinemann, V.
    Klinkhardt, U.
    Beier, F.
    Duecker, K.
    van Krieken, J. H.
    Tejpar, S.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 (10) : 1243 - 1252
  • [49] Feasibility of oxaliplatin and infusional fluorouracil/leucovorin (FOLFOX4) for Japanese patients with unresectable metastatic colorectal cancer
    Fuse, Nozomu
    Doi, Toshihiko
    Ohtsu, Atsushi
    Takeuchi, Satoshi
    Kojima, Takashi
    Taku, Keisei
    Tahara, Makoto
    Muto, Manabu
    Asaka, Masahiro
    Yoshida, Shigeaki
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2007, 37 (06) : 434 - 439
  • [50] PRIME STUDY: A RANDOMISED PHASE 3 STUDY OF PANITUMUMAB WITH FOLFOX4 VERSUS FOLFOX4 ALONE AS FIRST-LINE TREATMENT FOR METASTATIC COLORECTAL CANCER (mCRC)
    Siena, S.
    Douillard, J. Y.
    Tabernero, J.
    Cassidy, J.
    Burkes, R.
    Barugel, M. E.
    Humblet, Y.
    Cunningham, D.
    Wolf, M.
    Gansert, J.
    ANNALS OF ONCOLOGY, 2010, 21 : I13 - I13
12345